fenofibric acid has been researched along with gemfibrozil in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.69) | 18.7374 |
1990's | 4 (30.77) | 18.2507 |
2000's | 4 (30.77) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brinkjost, T; Ehrt, C; Koch, O | 1 |
Kashihara, M; Mizuguchi, M; Yokoyama, T | 1 |
Santafé Oroz, J; Segarra Domènech, J | 1 |
Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
Walsh, KB; Wang, C | 1 |
Kockx, M; Kooistra, T; Princen, HM | 1 |
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
Bauman, JN; Davis, JA; Goosen, TC; Hurst, SI; Loi, CM; Williams, JA; Yu, C | 1 |
Chen, J; Li, C; Lu, Y; Peijnenburg, WJGM; Qu, J; Xie, Q; Zhang, YN; Zhao, J; Zhou, Y | 1 |
2 review(s) available for fenofibric acid and gemfibrozil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
11 other study(ies) available for fenofibric acid and gemfibrozil
Article | Year |
---|---|
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Models, Chemical; Proteins | 2016 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole | 2021 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Effect of chloride channel blockers on the cardiac CFTR chloride and L-type calcium currents.
Topics: Animals; Anthracenes; Calcium; Calcium Channel Blockers; Chloride Channels; Chlorides; Clofibric Acid; Colforsin; Cystic Fibrosis Transmembrane Conductance Regulator; Fenofibrate; Gemfibrozil; Glycolates; Guinea Pigs; Ion Transport; Mice; Myocardium; ortho-Aminobenzoates; Patch-Clamp Techniques; Stilbenes | 1996 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides | 2001 |
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Catalysis; Drug Interactions; Fenofibrate; Gemfibrozil; Glucuronic Acid; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Microsomes, Liver; Models, Biological; Molecular Structure; Pyrroles; Recombinant Proteins; Tandem Mass Spectrometry; Uridine Diphosphate Glucuronic Acid | 2007 |
Unveiling the important roles of coexisting contaminants on photochemical transformations of pharmaceuticals: Fibrate drugs as a case study.
Topics: China; Fenofibrate; Gemfibrozil; Hydrogen-Ion Concentration; Light; Models, Theoretical; Molecular Structure; Pharmaceutical Preparations; Photolysis; Rivers; Water Pollutants, Chemical | 2018 |